Price Target Adjustment#
Evercore ISI has decreased its price target for GE HealthCare shares from $85 to $80 while maintaining an Outperform rating. This adjustment comes after a notable 12% drop in the stock price, which is now trading around $59.85, close to its 52-week low.
Earnings and Valuation Insights#
The firm highlighted a 5% cut in earnings per share, which has contributed to the stock's decline. Despite this, analysis suggests that GE HealthCare may be undervalued, currently holding a price-to-earnings (P/E) ratio of 13.17, indicating that the stock price is relatively low compared to its earnings. The company has remained profitable over the past year, which supports this valuation perspective.
Business Performance and Growth Prospects#
In terms of business performance, GE HealthCare has seen strong demand, with capital business-to-business orders exceeding 1.10 times and photon-counting CT orders reaching approximately $100 million shortly after receiving FDA approval. The company’s Flyrcado product is also expanding, potentially achieving an annual revenue run rate of about $200 million by the end of fiscal year 2026.
Future Outlook#
Looking ahead, GE HealthCare anticipates mid-single-digit growth in fiscal year 2027, bolstered by a solid order backlog. Despite facing challenges such as inflation impacting margins, the company expects improvements in gross margins in the second half of the year due to new product launches and cost management strategies. Recent earnings reports indicate a revenue of $5.1 billion for Q1 2026, marking a 2.9% organic growth year-over-year, although profitability concerns remain due to margin pressures.